Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2026-03-27 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
董事会审计委员会对会计师事务所2025年度履职情况评估及履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from the Board Audit Committee evaluating the performance of the accounting firm (DaXin CPA Firm) for the fiscal year 2025. It discusses the audit procedures, the audit firm's qualifications, the audit results including financial statements and internal control audits, and the committee's supervision activities. The document references the 2025 annual report and audit work related to the full fiscal year 2025. It is not the annual report itself but a standalone audit-related report focusing on the audit firm's performance and supervisory role. The document length is 2616 characters, which is relatively short but contains substantive audit evaluation content rather than just an announcement or certification. Therefore, it fits best under the category of Audit Report / Information (AR). FY 2025
2026-03-27 Chinese
非经营性资金占用及其他关联资金往来情况汇总表的专项审计报告
Audit Report / Information Classification · 95% confidence The document is an audit report issued by a certified public accounting firm regarding a specific financial matter: the non-operating funds occupation and other related party fund transactions summary table for the year 2025 of Yunnan Watson Biotechnology Co., Ltd. It includes the auditor's responsibilities, management responsibilities, audit procedures, and audit opinion. The document references the audit of the company's 2025 financial statements but focuses specifically on the audit of the non-operating funds occupation and related party transactions summary table, which is a specialized audit report rather than the full annual report or financial statements. The document is titled as a "专项审计报告" (special audit report) and contains detailed audit findings and opinions. It is not a full annual report (10-K), nor a general audit report of the entire financial statements (AR), but a standalone audit report on a specific issue. Therefore, the best fitting category is Audit Report / Information (AR). The document length is 3523 characters, which is sufficient to contain substantive audit content, not just an announcement or certification. Hence, classification as AR is appropriate with high confidence. FY 2025
2026-03-27 Chinese
2025年非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 95% confidence The document is a financial summary table detailing non-operating fund occupation and other related party fund transactions for the year 2025 for Yunnan Watson Biotechnology Co., Ltd. It includes accounting subjects, amounts at the beginning and end of the year, interest, repayments, and the nature of the transactions. The document is short (1315 characters) and primarily tabular data without narrative or comprehensive financial statements. It does not represent a full annual or interim report, nor is it an announcement or certification. It is a detailed financial disclosure related to related-party transactions, which typically falls under Regulatory Filings (RNS) as it does not fit the definitions of other specific report types such as Annual Report, Interim Report, or Audit Report. Therefore, the best classification is Regulatory Filings (RNS).
2026-03-27 Chinese
关于受让子公司玉溪沃森少数股权的进展暨玉溪沃森完成工商变更登记的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Yunnan Watson Biotechnology Co., Ltd. regarding the progress of acquiring minority equity interests in its subsidiary Yuxi Watson and the completion of the subsidiary's industrial and commercial registration change. It details specific share transfer agreements, board meeting approvals, and the updated shareholding percentage. The document is an official notice about changes in the company's subsidiary ownership and related corporate registration updates. It does not contain financial statements, audit information, or detailed financial performance data. It is not a report or presentation but an announcement of corporate actions related to capital structure changes within subsidiaries. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is short and focused on shareholding changes, not a full report or regulatory filing.
2026-03-19 Chinese
详式权益变动报告书
Major Shareholding Notification Classification · 95% confidence The document is titled '云南沃森生物技术股份有限公司 详式权益变动报告书' which translates to 'Detailed Equity Change Report of Yunnan Watson Biotechnology Co., Ltd.' It is a detailed report about the change in equity ownership, specifically about the subscription of shares by a particular entity (北京腾云新沃生物科技合伙企业). The document includes detailed information about the equity holder, the nature of the share change (increase by subscription), legal references to securities law and disclosure rules, and detailed descriptions of the ownership structure and control relationships. This type of document corresponds to a Major Shareholding Notification, which reports changes in significant share ownership levels, often required by securities regulators when ownership crosses certain thresholds or when there is a significant transaction involving shares. The document is lengthy (15,000 characters) and contains substantive information about the shareholding change, not just an announcement or a brief notice. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2026-03-19 Chinese
中信证券股份有限公司关于云南沃森生物技术股份有限公司详式权益变动报告书之财务顾问核查意见
Regulatory Filings Classification · 95% confidence The document is titled as a "详式权益变动报告书之财务顾问核查意见" which translates to "Detailed Equity Change Report - Financial Advisor's Verification Opinion." It references Chinese securities laws and regulations related to equity changes and disclosures, and it is issued by a financial advisor (中信证券股份有限公司) providing verification on the detailed equity change report of 云南沃森生物技术股份有限公司. The content includes detailed due diligence, verification of the equity change report, and opinions on the legality and accuracy of the disclosed information. This document is not the equity change report itself but the financial advisor's verification opinion on that report. Such verification opinions are typically part of regulatory filings related to equity changes but are not the equity change report or a capital/financing update per se. Given the detailed nature and the focus on verification of an equity change report, this fits best under Regulatory Filings (RNS) as it does not match other categories like Capital/Financing Update (CAP) or Share Issue/Capital Change (SHA) which would be more about announcements or the report itself. The document length and detail also exclude it from being a simple announcement or report publication announcement. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2026-03-19 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.